Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Recovery time 15% Improvement Relative Risk Time to viral- 16% Time to viral- (b) 16% Paxlovid for COVID-19  Zhong et al.  EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 142 patients in China (April - May 2022) Faster viral clearance with paxlovid (p=0.009) c19early.org Zhong et al., Frontiers in Medicine, Sep 2022 Favors paxlovid Favors control

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial

Zhong et al., Frontiers in Medicine, doi:10.3389/fmed.2022.980002, ChiCTR2200060700
Sep 2022  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 106 paxlovid and 36 control patients in China, showing faster viral clearance with treatment.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
recovery time, 14.7% lower, relative time 0.85, p = 0.26, treatment mean 4.81 (±3.0) n=106, control mean 5.64 (±2.87) n=36.
time to viral-, 15.8% lower, relative time 0.84, p = 0.009, treatment mean 7.51 (±2.79) n=106, control mean 8.92 (±2.61) n=36, viral shedding after enrollment.
time to viral-, 16.1% lower, relative time 0.84, p = 0.001, treatment mean 9.32 (±2.78) n=106, control mean 11.11 (±2.67) n=36, first positive to first of two negative tests.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhong et al., 6 Sep 2022, retrospective, China, peer-reviewed, 12 authors, study period 24 April, 2022 - 28 May, 2022, trial ChiCTR2200060700.
Contact: snailliyi@163.com, zhangwench88@hotmail.com, zhuchuanlong@jsph.org.cn.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
Weijie Zhong, Xiufeng Jiang, Xiaosheng Yang, Tiantong Feng, Zhixin Duan, Wei Wang, Zhaoliang Sun, Lingyan Chen, Xin Nie, Chuanlong Zhu, Wenchuan Zhang, Yi Li
Frontiers in Medicine, doi:10.3389/fmed.2022.980002
The efficacy of Paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial.
Ethics statement The studies involving human participants were reviewed and approved by the Ethics Committee of the Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (No. SH9H-2022-T112-2). Moreover, it was registered at the Chinese Clinical Trial Registry (ChiCTR2200060700). The patients/participants provided their written informed consent to participate in this study. Author contributions WJZ, XJ, XY, ZD, WW, ZS, WCZ, LC, and YL collected the epidemiological and clinical data. WCZ and YL were responsible for enrollment, clinical monitoring, funding, study conception and design, and revising and submitting the final manuscript. XY, ZD, XJ, and YL were responsible for the distribution and storage of medicines. WJZ, TF, XN, LC, CZ, YL, and WCZ were responsible for statistical data. WJZ, XJ, XY, TF, CZ, and YL drafted the manuscript. All authors contributed to the article and approved the submitted version. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the..
References
Carreño, Alshammary, Tcheou, Singh, Raskin et al., Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron, Nature, doi:10.1038/d41586-021-03846-z
Chilamakuri, Agarwal, COVID-19: characteristics and therapeutics, Cells, doi:10.3390/cells10020206
Dejnirattisai, Huo, Zhou, Zahradník, Supasa et al., SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell
Fan, Li, Zhang, Wan, Zhang et al., SARS-CoV-2 Omicron variant: recent progress and future perspectives, Signal Transduct Target Ther, doi:10.1038/s41392-022-00997-x
Fiolet, Kherabi, Macdonald, Ghosn, Peiffer-Smadja, Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review, Clin Microbiol Infect, doi:10.1016/j.cmi.2021.10.005
Garcia-Beltran, Denis, Hoelzemer, Lam, Nitido et al., mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant, doi:10.1101/2021.12.14.21267755
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hirabara, Serdan, Gorjao, Masi, Pithon-Curi et al., SARS-COV-2 variants: differences and potential of immune evasion, Front Cell Infect Microbiol, doi:10.1016/S2213-2600(21)00559-2
Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 and COVID-19
Hung, Lee, Chiu, Lee, Tsai et al., Oral nirmatrelvir/ritonavir therapy for COVID-19: the dawn in the dark?, Antibiotics, doi:10.3390/antibiotics11020220
Jose, Manuel, COVID-19 cytokine storm: the interplay between inflammation and coagulation, Lancet Respir Med, doi:10.1016/S2213-2600(20)30216-2
Kawaoka, Uraki, Kiso, Iida, Imai et al., Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2, Res Sq, doi:10.21203/rs.3.rs-1375091/v1
Ledford, How severe are Omicron infections?, Nature, doi:10.1038/d41586-021-03794-8
Marzi, Vakil, Bahmanyar, Zarenezhad, Paxlovid: mechanism of action, synthesis, and in silico study, Biomed Res Int, doi:10.1155/2022/7341493
Mistry, Barmania, Mellet, Peta, Strydom et al., SARS-CoV-2 variants, vaccines, and host immunity, Front Immunol, doi:10.3389/fimmu.2021.809244
Rössler, Riepler, Bante, Laer, Kimpel, SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons, N Engl J Med, doi:10.1056/NEJMc2119236
Shen, Lin, Zhang, Li, Wang, Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome coronavirus 2 in Houston, Texas, Emerg Microb Infect, doi:10.1016/j.ajpath.2022.01.007
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2, N Engl J Med, doi:10.1056/NEJMc2201933
Wang, Cheng, Zhang, Zhang, Chen, Shanghai's life-saving efforts against the current Omicron wave of the COVID-19 pandemic, J Med Virol, doi:10.1016/S0140-6736(22)00838-8
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit